Lagevrio^® (molnupiravir) PBS listing

Page last updated: 1 March 2022

Updated September 2022

Commencing 1 March 2022 Lagevrio^® (molnupiravir) will be listed on the Pharmaceutical Benefits Scheme (PBS) Section 85 program as an Authority Required (Streamlined) benefit for patients with mild-moderate COVID 19 who have a high risk for developing severe disease, reducing the need for admission to hospital.